Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Preschool Bolsters Early Childhood Immunity, Reduces Risk of Young Adult Hodgkin's Lymphoma

Main Category: Lymphoma / Leukemia / Myeloma
Article Date: 07 Aug 2004 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Children who attend day care or nursery school for at least one year before going to kindergarten are about 36 percent less likely than those not in preschool to develop Hodgkin's lymphoma as young adults, according to scientists reporting in this month's edition of the journal Cancer Epidemiology, Biomarkers & Prevention.

Earlier research indicated that higher childhood socioeconomic status and delayed infection with the prevalent Epstein-Barr virus were important predictors of Hodgkin's lymphoma in young adulthood. Because attending nursery school or day care favors earlier exposure to common childhood infections, the study supports the hypothesis that delayed infection increases the risk of young-adult Hodgkin's lymphoma, but fails to uphold the link to socioeconomic factors.

The research also shows that Hodgkin's lymphoma among adults aged 55 and over is associated with lower socioeconomic status, but not preschool attendance, indicating the existence of a separate mechanism for the development of Hodgkin's lymphoma in the two age groups.

"Years of epidemiological evidence have linked the risk of Hodgkin's lymphoma among young adults to high maternal education, few siblings, low housing density, and other aspects of higher childhood socioeconomic status," noted lead author Ellen T. Chang, Sc.D., of the Harvard School of Public Health. "It has been believed that these characteristics postpone childhood exposure to common pathogens, including the usually harmless Epstein-Barr virus, which can cause infectious mononucleosis when infection is delayed until adolescence. Infectious mononucleosis is a demonstrated risk factor for Hodgkin's lymphoma. However, we found no association between any of these factors and Hodgkin's lymphoma risk."

Chang went on to explain that how and when a child's immune system matures, as well as changes in the social environment of preschool aged children in the United States, account primarily for the differences in her team's results from those of their predecessors.

"At birth," she said, "infants are skewed toward type 2 helper T-cell immunity - or Th2 - which is characterized by the B-cell antibody-mediated response to infections by parasites, helminths or nematodes.

"In contrast, the phagocyte-dependent, inflammatory Th1 immune response matures with age, and does so in response to exposure to such Th1-stimulatory antigens as intracellular bacteria and viruses. These include but are not limited to Epstein-Barr virus.

"Children who are sheltered from contact with Th1-type antigens continue to be biased toward Th2 immunity, which promotes the development of asthma and other atopic conditions."

The team, which includes researchers from Yale University and the Johns Hopkins Medical Institute along with Chang, analyzed data for 565 cases of Hodgkin's lymphoma and 679 healthy controls among residents of the Boston area and Connecticut.

They were prompted to undertake the research in part to test the hypothesis that demographic changes in the United States in recent years might have modified previously reported associations between Hodgkin's lymphoma and childhood social factors. Enrollment in nursery school, for example, has risen from five percent in 1964 to 50 percent between 1995 and 1999.

Advances in women's education, increases in the number of single-parent and two-working parent household and reductions overall in family sizes all contribute to this dramatic rise in nursery school and day care enrollment.

"As parents of young children know well, the rate of exposure to childhood infections is high when groups of children spend time in close proximity, as is the case in day care and nursery school settings," added Chang. "This frequent contact appears to prime the immune system toward a more mature type 1 response than is found among children of the same age who have less social interaction with their peers. It also promotes earlier exposure to common childhood infections, such as the Epstein-Barr virus."

The results of the research were quite different, however, for the cases of Hodgkin's lymphoma developed later in life, at age 55 and older.

Said Chang: "Hodgkin's lymphoma is unusual among malignancies in having a distinct, two-phase incidence profile. In developed countries, the initial peak occurs among young adults aged 15 to 39, and the second peak from the mid-50s onward. Our study found no significant association between preschool attendance and risk of HL in adults aged 55 to 70, suggesting a different model for the etiology of the disease at late-adult onset," she concluded.

Further, Chang and her colleagues found that the incidence of Hodgkin's lymphoma among young adults in Boston and Connecticut appears to have dropped between 1997 and 2000, another trend that could be attributable to higher preschool attendance.

The study was supported by funds from National Cancer Institute grants P01 CA069266-01A1 and T32 CA09001-24.

Founded in 1907, the American Association for Cancer Research (AACR) is a professional society of more than 22,000 laboratory and clinical scientists engaged in basic, translational, and clinical cancer research in the United States and over 60 other countries. The AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals (Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention). The AACR's Annual Meeting attracts more than 15,000 participants who share new and significant discoveries in the cancer field, and the AACR's specialty meetings throughout the year focus on all the important areas of basic, translational, and clinical cancer research.

Contact:
Elizabeth J. Tait
Phone: 215/440-9300 Ext. 144
E-mail: tait@aacr.org
http://www.aacr.org/2004presst.asp


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Forum Icon

Lymphoma Forum

Discuss issues relating to lymphoma / leukemia / myeloma in our new forum.

Visit the lymphoma forum


These are the most read articles from this news category for the last 6 months:
Top Article Star
Allos Therapeutics' FOLOTYN™ First And Only FDA-Approved Therapy For Relapsed Or Refractory Peripheral T-cell Lymphoma
28 Sep 2009
Allos Therapeutics, Inc. (Nasdaq:ALTH) announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...